To date, intravitreal VEGF inhibitor administration monotherapy has been a standard treatment for exudative AMD, except for a specific AMD subtype, polypoidal choroidal vasculopathy (PCV) or pachychoroid neovasculopathy [10]. This evidence concerns the gene VEGFA and age-related macular degeneration.